Navigation Links
Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations
Date:8/16/2012

ALLEGAN, Mich., Aug. 16, 2012 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced results for its fourth quarter and full year ended June 30, 2012.

(Logo:  http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

Perrigo's Chairman and CEO Joseph C. Papa commented, "For the sixth straight year, we delivered year-over-year record sales and earnings while continuing to make investments in our facilities and production processes which we believe will further enhance our own already high standards of excellent product quality. During this fiscal year, we also announced the acquisition of CanAm Care to broaden our diabetes category offerings, multiple supply agreements for infant formula in China and numerous new product launches. The penetration of store brand share in the U.S. market continues to gain momentum as retailers and patients continue to turn to high quality, affordable alternatives for their healthcare needs. We look forward to another great year, with many new products in the pipeline across all segments."

Refer to Table I at the end of this press release for adjustments in the current year and prior year periods and additional non-GAAP disclosure information.

The Company's reported results are summarized in the attached Consolidated Statements of Income, Balance Sheets and Cash Flows.Perrigo Company
(from continuing operations, in thousands, except per share amounts)
(see the attached Table I for reconciliation to GAAP numbers)

 Fourth Quarter

Fiscal Year2012

2011

2012

2011Net Sales

$831,767

$704,629

$3,173,249

$2,755,029Reported Income

$107,050

$85,570

$392,974

$340,558Adjusted Income

$120,946

$95,418
'/>"/>

SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Perrigo Receives FDA Approval And Commences Launch Of Morphine Sulfate 100ml/5% Oral Solution
2. China Biologic Reports Financial Results for the Second Quarter and First Half of 2012
3. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
4. Avanir Pharmaceuticals Reports Fiscal 2012 Third Quarter Financial And Business Results
5. Savient Pharmaceuticals Reports Second Quarter 2012 Financial Results
6. Origin Agritech Limited Reports Unaudited Third Quarter Financial Results For Three Months Ended June 30, 2012
7. Verenium Reports Financial Results For The Second Quarter And Six Months Ended June 30, 2012
8. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
9. Discovery Labs Reports Second Quarter 2012 Financial Results
10. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
11. Cambrex Reports Second Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2014)... The “Fluid Management & Visualization Systems ... market with an analysis and forecast of value ... fluid warming and waste management. Along with this, ... systems by applications and regions are also discussed ... at $19,285.5 million in 2013 and is expected ...
(Date:11/15/2014)... The redesigned ActiGraph Link expands upon ... measurement platform with a rich feature set that ... new channels of sensor data captured by a ... Smart technology, the ActiGraph Link supports wireless heart ... ActiGraph’s cloud-based Study Admin platform, giving academic and ...
(Date:11/15/2014)... The "Operating Room Management Market by Product ... Preoperative, operating room Scheduling), by Component (Software, Services), ... to 2019.” defines and segments the operating room ... value by product, such as data management, anesthesia, ... and volumes of operating room management market by ...
(Date:11/15/2014)... 2014 Algenol Biofuels will present at CleanEquity Monaco ... of Monaco . Logo - ... annual invitation-only event hosted by Innovator Capital, the ... partners and sponsors include Prince Albert II of ... University, PR Newswire, the Monte-Carlo SBM, Oceanographic Museum of ...
Breaking Biology Technology:Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 2Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 3Fluid Visualization Systems Market poised to reach $25,908.4 Million by 2018 - New Research Report by MarketsandMarkets 4ActiGraph Launches GT9X Link Activity Monitor 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 2Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 3Operating Room Management Market Worth $4,551.1 Million by 2019 - New Report by MarketsandMarkets 4Algenol Biofuels Selected to Present at CleanEquity Monaco 2015 2
... Nov. 7 Interleukin Genetics,Inc. (Amex: ILI ), ... and genetic tests for sale to the,emerging personalized health ... 30, 2007. The Company recorded revenue of $2.6 ... million for third quarter ended September 30,2006, a 92% ...
... Function and Tissue Preservation ... in Spinal Cord Injury Model, SAN DIEGO, Nov. ... today the presentation of preclinical data from,its ZFP Therapeutic(TM) ... Meeting of the Society for Neuroscience. A statistically,significant effect ...
... Nov. 7 SyntheMed, Inc. (OTC,Bulletin Board: SYMD), ... of anti-adhesion, tissue repair and drug delivery,products, announced ... registration,statement with the Securities and Exchange Commission (SEC) ... SyntheMed to sell, from time to,time, up to ...
Cached Biology Technology:Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 2Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 3Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 4Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 5Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results 6Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 2Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 3Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 4Sangamo BioSciences Announces ZFP Therapeutic Data From Nerve Regeneration Program at Society for Neuroscience Meeting 5SyntheMed Files Universal Shelf Registration 2
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/4/2014)... Nov. 4, 2014   Neurotechnology , a ... that the latest version of its fingerprint matching ... Ongoing MINEX evaluation organized by NIST. The ... using the INCITS 378 fingerprint standard template format. ... public tenders in the United States ...
(Date:11/3/2014)... published in this month,s Proceedings of the ... a recently discovered communication molecule of the body,s immune ... to limit inflammation and the current study reports its ... ability of the immune system to recognize and target ... effect on the immune system now allows us to ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... who study HIV are facing a troubling consequence of their ... patients almost normal life expectancy. However, those same drugs will ... form that eludes current treatments. With a new $3.4 ... of Missouri is leading a team of researchers who want ...
... in the eye often are fatal. Now, scientists at Washington ... identified a mutated gene in melanoma tumors of the eye ... is published in the advance online edition of Nature ... SF3B1," says senior author Anne Bowcock, PhD, professor of genetics. ...
... TEMPE, Ariz.---Arizona State University,s Biodesign Institute has announced ... enters the next phase of a multi-million-dollar, multi-institutional ... rapidly assess an individual,s exposure to radiation in ... project enters a $9.33 million contract option as ...
Cached Biology News:Researchers attack HIV's final defenses before drug-resistant mutations emerge 2Researchers attack HIV's final defenses before drug-resistant mutations emerge 3Gene in eye melanomas linked to good prognosis 2ASU partners with Life Technologies on US DHHS funded project to rapidly assess radiation dose 2
... The CHEMICON® CaspaTag™ Caspase-9 Pan-Caspase In ... assay for detection of active caspases in ... research use only. Not for use in ... Situ Caspase Detection Kits use a novel ...
... The transformation of Saccharomyces cerevisiae, as ... routine procedure in many molecular biology laboratories. ... high efficiencies with plasmid and linear DNAs ... has made routine plasmid transformations and library ...
... a fluorescein-conjugated jetSI-ENDO (excitation ... 520 nm), the powerful siRNA ... used to determine the transfection ... delivery and trafficking of siRNAs. ...
... for high efficiency siRNA delivery ... reagent proven to work effectively ... cell types. Results in silencing ... target gene expression. One step, ...
Biology Products: